INmune Bio Valuation
| INMB Stock | USD 4.88 0.08 1.67% |
At this time, the firm appears to be undervalued. INmune Bio retains a regular Real Value of $7.83 per share. The prevalent price of the firm is $4.88. Our model calculates the value of INmune Bio from evaluating the firm fundamentals such as Return On Asset of -0.45, return on equity of -0.99, and Shares Outstanding of 22.17 M as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting INmune Bio's valuation include:
Price Book 2.7518 | Enterprise Value 75.8 M | Enterprise Value Ebitda (5.31) | Price Sales 2.5 K | Enterprise Value Revenue 1.8 K |
Undervalued
Today
Please note that INmune Bio's price fluctuation is slightly risky at this time. Calculation of the real value of INmune Bio is based on 3 months time horizon. Increasing INmune Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since INmune Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of INmune Stock. However, INmune Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.88 | Real 7.83 | Target 17.33 | Hype 4.98 |
The real value of INmune Stock, also known as its intrinsic value, is the underlying worth of INmune Bio Company, which is reflected in its stock price. It is based on INmune Bio's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of INmune Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of INmune Bio helps investors to forecast how INmune stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of INmune Bio more accurately as focusing exclusively on INmune Bio's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use INmune Bio's intrinsic value based on its ongoing forecasts of INmune Bio's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against INmune Bio's closest peers. If more than one evaluation category is relevant for INmune Bio we suggest using both methods to arrive at a better estimate.
INmune Bio Cash |
|
INmune Valuation Trend
Comparing INmune Bio's enterprise value against its market capitalization is a good way to estimate the value of INmune Bio uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
INmune Bio Total Value Analysis
INmune Bio is currently expected to have valuation of 75.79 M with market capitalization of 106.43 M, debt of 10.44 M, and cash on hands of 61.21 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the INmune Bio fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
75.79 M | 106.43 M | 10.44 M | 61.21 M |
INmune Bio Investor Information
About 29.0% of the company shares are held by company insiders. The book value of INmune Bio was currently reported as 1.74. The company recorded a loss per share of 2.18. INmune Bio had not issued any dividends in recent years. Based on the analysis of INmune Bio's profitability, liquidity, and operating efficiency, INmune Bio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.INmune Bio Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. INmune Bio has an asset utilization ratio of 0.27 percent. This suggests that the Company is making $0.002719 for each dollar of assets. An increasing asset utilization means that INmune Bio is more efficient with each dollar of assets it utilizes for everyday operations.INmune Bio Ownership Allocation
INmune Bio has a total of 22.17 Million outstanding shares. INmune Bio secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.INmune Bio Profitability Analysis
The company reported the previous year's revenue of 155 K. Net Loss for the year was (30.01 M) with profit before overhead, payroll, taxes, and interest of 374 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates INmune Bio's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in INmune Bio and how it compares across the competition.
About INmune Bio Valuation
The stock valuation mechanism determines INmune Bio's current worth on a weekly basis. Our valuation model uses a comparative analysis of INmune Bio. We calculate exposure to INmune Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of INmune Bio's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 155 K | 147.2 K | |
| Pretax Profit Margin | (193.60) | (203.28) | |
| Operating Profit Margin | (191.88) | (201.47) | |
| Net Loss | (193.60) | (203.28) |
INmune Bio Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 18 M |
INmune Bio Current Valuation Indicators
Valuation refers to the process of determining the present value of INmune Bio and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value INmune we look at many different elements of the entity such as INmune's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as INmune Bio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use INmune Bio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes INmune Bio's worth.Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |